key: cord-1006711-83x9sgoh authors: Fu, Qibo; Zheng, Xiao; Zhou, Yunlian; Tang, Lanfang; Chen, Zhimin; Ni, Shaoqing title: Re-recognizing bromhexine hydrochloride: pharmaceutical properties and its possible role in treating pediatric COVID-19 date: 2020-09-01 journal: Eur J Clin Pharmacol DOI: 10.1007/s00228-020-02971-4 sha: ae12de80e0350c1260b80741c1b40f05ef65da70 doc_id: 1006711 cord_uid: 83x9sgoh nan The outbreak of coronavirus disease 2019 (COVID- 19) caused by SARS-coronavirus 2 (SARS-CoV-2) has become a pandemic and constitutes a global health emergency [1] . The number of infected children is increasing, with reports of children's deaths [2] [3] [4] [5] [6] . As with adults, no effective anti-COVID-19 therapy has been found yet for children [7] [8] [9] [10] . Researchers from Germany recently provided evidence that the transmembrane protease serine 2 (TMPRSS2) plays a key role in SARS-CoV-2 binding to the host cell receptor, thereby achieving viral invasion and infection [11] . Other studies also suggest that TMPRSS2 is a drug target for treating COVID-19, and bromhexine was found to be a strong inhibitor of TMPRSS2 [12] [13] [14] . Bromhexine hydrochloride is approved in many countries as a commonly used over-thecounter (OTC) expectorant for both adults and children and has been marketed since 1963 [15, 16] . It is characterized by low side effects and relatively low cost [17] . Considering all these characteristics, bromhexine hydrochloride could be an ideal candidate as a potential COVID-19 treatment [17] [18] [19] . As far as safety is concerned, the incidence of adverse reactions to bromhexine hydrochloride has been similar in children and adults. Though unlikely, if there are signs or symptoms of skin reactions or allergic reactions, patients should seek medical advice and discontinue bromhexine hydrochloride immediately [15] . It should be used with caution in the presence of obstructed bronchial motor function or large amounts of secretions [15] . Also, it is not recommended for use in children under 2 years of age owing to the risk of lifethreatening side effects [20] . According to the results of cell experiments, the half maximal inhibitory concentration (IC 50 ) of bromhexine hydrochloride on TMPRSS2 protease is 0.75 μM, and the target cell concentration is about 308.62 ng/mL [14] . The pharmacokinetic data for oral bromhexine hydrochloride show that the adult maximum blood concentration (C max ) with oral administration of 8 mg bromhexine hydrochloride is 22.50 ± 7.50 μg/L [21] , and the concentration in the parenchymal tissue of the lung is 54-132.75 ng/mL, far less than the concentration of target cells [22] . Because the new pharmacokinetic parameters of bromhexine hydrochloride are proportional to an oral dose of 8-32 mg [21] , the pulmonary concentration with 32 mg of the drug would be 216-531 ng/mL (median 373.5 ng/mL), which could achieve the target cell concentration to inhibit TMPRSS2. In adults, Yong et al. suggested an oral dose of bromhexine hydrochloride up to 96 mg per day in clinical practice [23] to maximize the drug concentration in blood. We did not find reports of pediatric use experiences [24] . As of June 12, 2020, six clinical trials have been registered to explore the therapeutic potential of oral bromhexine hydrochloride in patients with COVID-19. The only clinical trial in children was registered by our group [25] . The use of new therapeutic methods in children should be undertaken very cautiously, because the pathogenesis of COVID-19 in children is still not clear. After comprehensive consideration of age, pharmacokinetics and safety, we propose initially studying the use of bromhexine hydrochloride at the maximum dosage recommended by drug labels in pediatric patients with suspected and mild cases of COVID-19. The oral dose will depend on age as follows: 12 mg, 24 mg and 48 mg daily in three divided doses for ages 2-5 (weight < 50 kg), 6-13 * Zhimin Chen zmchen@zju.edu.cn * Shaoqing Ni chgcp@zju.edu.cn (weight ≥ 50 kg) and 14-18, respectively. However, we have not recruited patients because very few children have been diagnosed with COVID-19 in China thus far. We propose that the use of bromhexine hydrochloride in the treatment of pediatric COVID-19 be studied in clinical research and clinical practice to fight against the spread of COVID-19 throughout the world. World Health Organization (2020) Coronavirus disease (COVID-19) outbreak situation Report -145 Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue Analysis of CT features of 15 children with 2019 novel coronavirus infection First case of 2019 novel coronavirus infection in children in Shanghai 2019-novel coronavirus infection in a three-month-old baby First case of neonate infected with novel coronavirus pneumonia in China New coronavirus: new challenges for pediatricians Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement Pediatric Branch of Hubei Medical Association, Pediatric Branch of Wuhan Medical Association Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Airway proteases: an emerging drug target for influenza and other respiratory virus infections TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis Ambroxol and bromhexine Article 31 Referral-PRAC assessment report Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the transmembrane serine protease 2 Unexpected infant deaths associated with use of cough and cold medications Determination of Bromhexine in plasma by gas chromatography-electron capture detection and pharmacokinetic studies HPLC-MS assay for the determination of bromhexine in human plasma and application to Eur J Clin Pharmacol bioequivalence studies Potential mechanistic investigation of Bromhexine for the treatment of COVID-19 SARS-CoV-2 infection in children Chinese Clinical Trial Registry (2020) Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets in Treating Pediatric novel coronavirus pneumonia (COVID-19 Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Acknowledgements We would like to thank Prof. Hao Haiping for all his